CD79B and diffuse large B-cell lymphoma: While previous studies have shown the disruption of various cancer-associated mutations, our focus on targeting oncogenes such as PAX5, MYC, and CD79B in diffuse large B-cell lymphoma (DLBCL) represents a significant advancement (Honeywell et al., 2023; Montalbano et al., 2017).